Brief: Elevation Oncology To Present Initial Seribantumab Proof-Of-Concept Data From Phase 2 Crestone Study In Patients With Tumors Harboring Nrg1 Fusions At Asco 2022

Elevation Oncology

27/05/2022 24:53

May 26 (Reuters) - Elevation Oncology Inc  ELEV.O :
    * ELEVATION ONCOLOGY TO PRESENT INITIAL SERIBANTUMAB
PROOF-OF-CONCEPT DATA FROM PHASE 2 CRESTONE STUDY IN PATIENTS
WITH TUMORS HARBORING NRG1 FUSIONS AT ASCO 2022
    * ELEVATION ONCOLOGY - TOPLINE DATA FROM CRESTONE PHASE 2
STUDY
RESULTS ARE EXPECTED IN 2024
    * ELEVATION ONCOLOGY - SERIBANTUMAB HAS BEEN WELL-TOLERATED
IN
PATIENTS WITH TUMORS HARBORING NRG1 FUSIONS
    * ELEVATION ONCOLOGY - POSITIVE INITIAL DATA SUPPORT
POTENTIAL OF
SERIBANTUMAB TO INDUCE DURABLE BENEFIT FOR PATIENTS WITH TUMORS
HARBORING NRG1 FUSIONS
    * ELEVATION ONCOLOGY - CLINICAL ACTIVITY OBSERVED INCLUDES
33%
RESPONSE RATE WITH 2 COMPLETE RESPONSES ACROSS ALL TUMOR TYPES
HARBORING NRG1 FUSIONS
    * ELEVATION ONCOLOGY - SERIBANTUMAB DEMONSTRATED FAVORABLE
AND
TOLERABLE SAFETY PROFILE ACROSS 35 PATIENTS EVALUABLE FOR SAFETY
    * ELEVATION ONCOLOGY - ADDITIONAL INTERIM DATA FROM CRESTONE
PHASE
2 STUDY ARE EXPECTED IN FIRST HALF OF 2023

Source text for Eikon:  ID:nPn2356R0a 
Further company coverage:  ELEV.O 

 ((Reuters.Briefs@thomsonreuters.com;))